Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $482,000.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Heather Ann Mcsharry sold 2,000 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $241.00, for a total transaction of $482,000.00. Following the completion of the sale, the director directly owned 18,449 shares of the company’s stock, valued at approximately $4,446,209. This trade represents a 9.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $236.49 on Friday. Jazz Pharmaceuticals PLC has a 1-year low of $105.00 and a 1-year high of $243.32. The stock has a market cap of $14.84 billion, a PE ratio of -11,818.59, a price-to-earnings-growth ratio of 0.41 and a beta of 0.27. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The firm has a fifty day moving average price of $208.12 and a 200 day moving average price of $183.55.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The firm had revenue of $1.07 billion during the quarter. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 21.13 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its stake in shares of Jazz Pharmaceuticals by 11.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after acquiring an additional 298,815 shares during the period. Capital World Investors increased its stake in shares of Jazz Pharmaceuticals by 4.4% during the fourth quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock worth $453,322,000 after acquiring an additional 111,735 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Jazz Pharmaceuticals by 11.4% during the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock worth $198,159,000 after acquiring an additional 191,637 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Jazz Pharmaceuticals by 8.5% during the third quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock worth $246,092,000 after acquiring an additional 145,865 shares during the period. Finally, Franklin Resources Inc. increased its stake in shares of Jazz Pharmaceuticals by 164.0% during the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock worth $309,215,000 after acquiring an additional 1,129,995 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Zacks Research lifted near- and medium-term earnings forecasts for Jazz Pharmaceuticals, including FY2026 EPS to $21.72 from $18.70 and FY2027 EPS to $22.26 from $20.87, which suggests improving earnings power and supports a higher valuation.
• Positive Sentiment: Several quarterly estimates were also raised, including Q2 2026, Q3 2026, Q1 2027, Q3 2027, Q4 2027, and FY2028, reinforcing optimism around the company’s growth outlook.
• Positive Sentiment: The recent publication of Phase 3 HERIZON-GEA-01 results for Ziihera in The New England Journal of Medicine adds another potential catalyst by highlighting durable survival benefits in HER2+ gastroesophageal cancer. Article Title

Wall Street Analyst Weigh In

A number of brokerages have recently commented on JAZZ. Morgan Stanley reaffirmed an “overweight” rating and issued a $245.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, May 7th. Wells Fargo & Company upped their target price on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their target price for the company from $188.00 to $307.00 in a report on Tuesday, May 19th. Weiss Ratings raised shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $239.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $242.65.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.